CN114053342A - Composition for promoting defecation and application thereof - Google Patents
Composition for promoting defecation and application thereof Download PDFInfo
- Publication number
- CN114053342A CN114053342A CN202010774369.3A CN202010774369A CN114053342A CN 114053342 A CN114053342 A CN 114053342A CN 202010774369 A CN202010774369 A CN 202010774369A CN 114053342 A CN114053342 A CN 114053342A
- Authority
- CN
- China
- Prior art keywords
- culture
- lactic acid
- composition
- extract
- bacterial strain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 42
- 230000013872 defecation Effects 0.000 title claims abstract description 24
- 230000001737 promoting effect Effects 0.000 title claims abstract description 19
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 92
- 239000000284 extract Substances 0.000 claims abstract description 52
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 46
- 239000004310 lactic acid Substances 0.000 claims abstract description 46
- 206010010774 Constipation Diseases 0.000 claims abstract description 30
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 19
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 19
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 19
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract description 16
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 16
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims abstract description 16
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 13
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 13
- 241000186869 Lactobacillus salivarius Species 0.000 claims abstract description 13
- 241001134770 Bifidobacterium animalis Species 0.000 claims abstract description 8
- 229940118852 bifidobacterium animalis Drugs 0.000 claims abstract description 8
- NGFMICBWJRZIBI-JZRPKSSGSA-N Salicin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1c(CO)cccc1 NGFMICBWJRZIBI-JZRPKSSGSA-N 0.000 claims abstract description 7
- NGFMICBWJRZIBI-UHFFFAOYSA-N alpha-salicin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UHFFFAOYSA-N 0.000 claims abstract description 7
- NGFMICBWJRZIBI-UJPOAAIJSA-N salicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UJPOAAIJSA-N 0.000 claims abstract description 7
- 229940120668 salicin Drugs 0.000 claims abstract description 7
- 241001052560 Thallis Species 0.000 claims abstract description 5
- 230000001580 bacterial effect Effects 0.000 claims description 32
- 239000003814 drug Substances 0.000 claims description 17
- 235000013305 food Nutrition 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 3
- 210000000582 semen Anatomy 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 abstract description 23
- 241000186660 Lactobacillus Species 0.000 abstract description 9
- 229940039696 lactobacillus Drugs 0.000 abstract description 9
- 244000022372 Diospyros lotus Species 0.000 abstract description 5
- 235000003333 Diospyros lotus Nutrition 0.000 abstract description 5
- 229940027779 persimmon extract Drugs 0.000 abstract description 2
- 238000000034 method Methods 0.000 description 16
- 239000000047 product Substances 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 239000000843 powder Substances 0.000 description 12
- 238000004321 preservation Methods 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 6
- 235000013361 beverage Nutrition 0.000 description 5
- 235000015872 dietary supplement Nutrition 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 5
- 239000008267 milk Substances 0.000 description 5
- 210000004080 milk Anatomy 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000001694 spray drying Methods 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- 235000011511 Diospyros Nutrition 0.000 description 3
- 244000236655 Diospyros kaki Species 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229920002774 Maltodextrin Polymers 0.000 description 3
- 239000005913 Maltodextrin Substances 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 235000013325 dietary fiber Nutrition 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229940035034 maltodextrin Drugs 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 208000002881 Colic Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241001147746 Lactobacillus delbrueckii subsp. lactis Species 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 239000004376 Sucralose Substances 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 235000010358 acesulfame potassium Nutrition 0.000 description 2
- 229960004998 acesulfame potassium Drugs 0.000 description 2
- 239000000619 acesulfame-K Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000001668 ameliorated effect Effects 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000000799 cathartic agent Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 235000015140 cultured milk Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical class CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 229940030606 diuretics Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000000105 enteric nervous system Anatomy 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 235000021107 fermented food Nutrition 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 235000020510 functional beverage Nutrition 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 230000005176 gastrointestinal motility Effects 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 239000000832 lactitol Substances 0.000 description 2
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 2
- 235000010448 lactitol Nutrition 0.000 description 2
- 229960003451 lactitol Drugs 0.000 description 2
- 235000021374 legumes Nutrition 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 229940045184 malt extract Drugs 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 235000013379 molasses Nutrition 0.000 description 2
- 239000006872 mrs medium Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 229940066779 peptones Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 235000019408 sucralose Nutrition 0.000 description 2
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 108010046845 tryptones Proteins 0.000 description 2
- 238000007738 vacuum evaporation Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- KVZLHPXEUGJPAH-UHFFFAOYSA-N 2-oxidanylpropanoic acid Chemical compound CC(O)C(O)=O.CC(O)C(O)=O KVZLHPXEUGJPAH-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 235000009434 Actinidia chinensis Nutrition 0.000 description 1
- 244000298697 Actinidia deliciosa Species 0.000 description 1
- 235000009436 Actinidia deliciosa Nutrition 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 1
- 235000009685 Crataegus X maligna Nutrition 0.000 description 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 1
- 235000009486 Crataegus bullatus Nutrition 0.000 description 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 1
- 235000009682 Crataegus limnophila Nutrition 0.000 description 1
- 240000000171 Crataegus monogyna Species 0.000 description 1
- 235000004423 Crataegus monogyna Nutrition 0.000 description 1
- 235000002313 Crataegus paludosa Nutrition 0.000 description 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 241000908123 Hippodamia Species 0.000 description 1
- 244000017020 Ipomoea batatas Species 0.000 description 1
- 235000002678 Ipomoea batatas Nutrition 0.000 description 1
- 241000186712 Lactobacillus animalis Species 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 102100029677 Trehalase Human genes 0.000 description 1
- 108010087472 Trehalase Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 235000011850 desserts Nutrition 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- -1 elixirs (elixir) Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 235000020717 hawthorn extract Nutrition 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
Abstract
The present invention relates to a composition for promoting defecation and its application. The invention discloses a composition for promoting defecation, which comprises a dateplum persimmon extract, a cassia seed extract, a lotus leaf extract and a culture of a lactic acid bacteria strain, wherein the lactic acid bacteria strain is selected from the group consisting of: lactobacillus salivarius subspecies salicin AP-32(CCTCC M2011127), Bifidobacterium animalis subspecies lactis CP-9(CCTCC M2014588), Lactobacillus acidophilus TYCA06(CGMCC NO.15210), and combinations thereof, and the culture is substantially free of thalli. The invention also discloses a culture of the lactobacillus strain and the application of the composition in promoting defecation and treating and/or preventing constipation.
Description
Technical Field
The present invention relates to a composition for promoting defecation and use thereof.
Background
Constipation (constipation) is a symptom that stool stays in the large intestine for a long time due to the functional disorder of gastrointestinal motility (gastrointestinal motility), and water contained in the stool is absorbed to be dry and hard, thereby causing reduction in the number of times or amount of defecation, difficulty in defecation, or abdominal distension and pain. In addition, food ingested by the human body is easily decomposed by bacterial fermentation in the intestinal tract to produce toxic substances (e.g., aldehydes, ketones, ammonia, etc.), and when these toxic substances are not normally excreted, they are reabsorbed by the intestinal tract and enter the blood circulation, thereby causing various metabolic diseases (metabolic diseases).
The cause of constipation has a high correlation with dietary habits, and for example, insufficient intake of dietary fiber (dietary fiber) and water, lack of exercise, pregnancy, stress, anxiety, and irregular life may cause constipation. In addition, drugs such as analgesics (analgesic), diuretics (diuretics), antidepressants (anti-depressants) or hypotensive agents (hypotensive agents) may also cause constipation side effects (side effects) in patients.
The current methods for improving constipation mainly adjust diet and daily work and rest, for example, increase the intake of dietary fiber and water and proper exercise. When the above methods fail to achieve the desired effect, they are often used in combination with drugs such as cathartics (cathartics) or faecal agents (faecal agents). Although these drugs exert their therapeutic effects immediately, they tend to cause serious side effects in patients [ such as intestinal colic (intestinal colic), impairment of the enteric nervous system (enteric nervous system) ]. Therefore, related researchers in the field have attempted to find active components (active components) from natural sources (natural sources) that are available for treating constipation.
Related researchers have taken extracts from Chinese herbs such as black date, cassia seed, lotus leaf powder, hawthorn, plum, etc. or lactic acid bacteria such as Lactobacillus (Lactobacillus), Bifidobacterium (Bifidobacterium), etc. to be applied to the treatment of constipation (Jang s.h.et al (2018), Korean j.food & nutr.,31: 640-; and eriini Dimidi et al (2017), adv.nutr.,8: 484-494). However, the Chinese herbal medicines are generally not effective in a short period of time and need to be taken for a relatively long period of time. As for lactic acid bacteria, it is mainly used to colonize the intestinal tract to regulate the intestinal bacterial phase and further improve the intestinal health, but lactic acid bacteria are easily damaged by gastric acid and bile salt after being taken by human body, so that the number of lactic acid bacteria colonized in the intestinal tract is insufficient and the effect cannot be effectively exerted.
Therefore, how to treat constipation quickly and effectively without causing undesirable side effects has become an important research and development issue.
Disclosure of Invention
Accordingly, in a first aspect, the present invention provides a composition for promoting defecation, comprising an extract of dateplum persimmon, an extract of cassia seed, an extract of lotus leaf, and a culture of a lactic acid bacterial strain selected from the group consisting of: lactobacillus salivarius subsp.salicinus AP-32(CCTCC M2011127), Bifidobacterium animalis subsp.lactis CP-9(CCTCC M2014588), Lactobacillus acidophilus (Lactobacillus acidophilus) TYCA06(CGMCC NO.15210), and combinations thereof, and the culture is substantially free of bacterial cells.
The composition comprises 1-20% (w/w) of black date extract, 0.1-10% (w/w) of cassia seed extract, 0.1-10% (w/w) of lotus leaf extract and 1-10% (w/w) of culture of lactobacillus strains, based on the total weight of the composition.
In a second aspect, the present invention provides a food product comprising a composition as described above.
In a third aspect, the present invention provides the use of a supply of a composition as described above for the preparation of a medicament for promoting defecation.
In a fourth aspect, the present invention provides the use of a composition as described above for the preparation of a medicament for the treatment and/or prevention of constipation.
In a fifth aspect, the present invention provides the use of a culture of a lactic acid bacterial strain for the preparation of a medicament for promoting defecation, wherein the lactic acid bacterial strain is a strain selected from the group consisting of: lactobacillus salivarius subspecies salicin AP-32(CCTCC M2011127), Bifidobacterium animalis subspecies lactis CP-9(CCTCC M2014588), Lactobacillus acidophilus TYCA06(CGMCC NO.15210), and combinations thereof, and the culture is substantially free of thalli.
In a sixth aspect, the present invention provides the use of a culture of a lactic acid bacterial strain for the preparation of a medicament for the treatment and/or prevention of constipation, wherein the lactic acid bacterial strain is a strain selected from the group consisting of: lactobacillus salivarius subspecies salicin AP-32(CCTCC M2011127), Bifidobacterium animalis subspecies lactis CP-9(CCTCC M2014588), Lactobacillus acidophilus TYCA06(CGMCC NO.15210), and combinations thereof, and the culture is substantially free of thalli.
In a seventh aspect, the present invention provides a method for promoting defecation, comprising administering to an individual in need thereof a culture or composition of a lactic acid bacterial strain as described above.
In an eighth aspect, the invention provides a method for treating an individual having or suspected of having constipation, comprising administering to the individual a culture or composition of a lactic acid bacterial strain as described above.
The medicine is in a dosage form for oral administration.
Drawings
The above and other objects and features of the present invention will become more apparent by referring to the following description, claims accompanied with text and accompanying drawings, wherein:
figure 1 shows the percentage of people who increased and decreased the number of bowel movements in each group before and after taking the lactic acid bacteria drink of the present invention, wherein "+" indicates that p < 0.01 when compared to the control group; and ". x" indicates that p <0.001 when compared to the control group.
Detailed Description
For the purposes of this specification, it will be clearly understood that: the word "comprising" means "including but not limited to", and the word "comprising" has a corresponding meaning.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. Those skilled in the art will recognize many methods and materials similar or equivalent to those described herein, which can be used in the practice of the present invention. Of course, the present invention is in no way limited to the methods and materials described.
In developing a drug useful for treating and/or preventing constipation, the applicant found through experiments that a composition comprising an extract of dateplum persimmon, an extract of cassia seed, an extract of lotus leaf, and a culture of a lactic acid bacterium strain is effective in increasing the number of stools of a subject in a short time, and thus is expected to have the potential of promoting defecation (defecation) and treating and/or preventing constipation (constipation).
Accordingly, the present invention provides a composition for promoting defecation, comprising an extract of dateplum persimmon, an extract of cassia seed, an extract of lotus leaf, and a culture of a lactic acid bacterial strain selected from the group consisting of: lactobacillus salivarius subsp.salicinus AP-32(CCTCC M2011127), Bifidobacterium animalis subsp.lactis CP-9(CCTCC M2014588), Lactobacillus acidophilus (Lactobacillus acidophilus) TYCA06(CGMCC NO.15210), and combinations thereof, and the culture is substantially free of bacterial cells.
Preferably, the composition comprises, based on the total weight of the composition: 1-20% (w/w) of black date extract; 0.1-10% (w/w) of semen Cassiae extract; 0.1-10% (w/w) of lotus leaf extract; and 1-10% (w/w) of a culture of a lactic acid bacterial strain.
More preferably, the composition comprises, based on the total weight of the composition: 1-10% (w/w) of black date extract; 0.1-1% (w/w) of semen Cassiae extract; 0.1-1% (w/w) of lotus leaf extract; and 1-10% (w/w) of a culture of a lactic acid bacterial strain.
According to the invention, the extraction process of the black date extract can be carried out using a solvent selected from the group consisting of: water, methanol, ethanol, ethyl acetate, and combinations thereof. In a preferred embodiment of the present invention, the black date extract is prepared by extracting black dates (black dates) using water.
According to the present invention, the extraction process of the cassia seed extract can be carried out using a solvent selected from the group consisting of: water, methanol, ethanol, ethyl acetate, and combinations thereof. In a preferred embodiment of the present invention, the cassia seed extract is prepared by extracting cassia seed (cassia seed) with water.
According to the invention, the extraction process of the lotus leaf extract can be carried out using a solvent selected from the group consisting of: water, methanol, ethanol, ethyl acetate, and combinations thereof. In a preferred embodiment of the invention, the lotus leaf extract is prepared by extracting lotus leaves (lotus leaves) with water.
It can be understood that the operating conditions related to the above extraction method will further vary depending on the treatment method of the Chinese herbal medicine used, the dosage ratio of the Chinese herbal medicine, and other factors, so as to achieve the best extraction effect. The choice of these operating conditions is within the routine discretion of the skilled person.
In addition, the compositions according to the present invention may further comprise other additional extracts, including, but not limited to: plum extract, hawthorn extract, kiwi extract, sweet potato extract, and apple extract.
According to the invention, the culture of the lactic acid bacterial strain is obtained by culturing Lactobacillus salivarius subspecies salicin AP-32(CCTCC M2011127), Bifidobacterium animalis subspecies Lactobacillus lactis CP-9(CCTCC M2014588) and Lactobacillus acidophilus TYCA06(CGMCC NO.15210) in a liquid medium suitable for the growth of these strains, followed by the removal of the bacterial bodies using a separation treatment.
As used herein, the terms "culturing", "fermentation" and "cultivation" are used interchangeably.
Liquid media suitable for culturing these strains according to the present invention are well known to those skilled in the art and include, but are not limited to: MRS broth (MRS broth).
According to the present invention, the liquid medium suitable for use in the present invention comprises a carbon source selected from the group consisting of: glucose (glucose), fructose (fructose), lactose (lactose), sucrose (sucrose), maltose (maltose), galactose (galactose), mannose (mannose), trehalose (trehalase), starch (starch), molasses (molasses), potato starch (potatoto starch), corn starch (corn starch), malt extract (maltextract), maltodextrin (maltdextrin), and combinations thereof.
According to the invention, the liquid medium suitable for use in the invention comprises a nitrogen source selected from the group consisting of: (NH4)2SO4、(NH4)3PO4、NH4NO3、NH4Cl, casamino acids (casamino acids), urea (urea), peptones (peptones), polypeptones (polypeptones), tryptones (tryptones), meat extracts (meat extracts), yeast extracts (yeast extracts), yeast powders (yeast powder), milk powder, soy flour (soybean flours) or other legume products, whey, and combinations thereof. Preferably, the nitrogen source comprises milk, milk powder, casein, soybean powder and legumes.
The procedures and parameters concerning the cultivation, and the like, are within the scope of professional literacy and routine skill of those skilled in the art. In this regard, reference may be made, for example, to Hsieh P.S.et al. (2013), New Microbiol.,36: 167-.
According to the invention, the cultivation is carried out at a temperature falling within the range of 30 ℃ to 40 ℃.
According to the invention, the cultivation is carried out for a period of time falling within the range of 12 to 24 hours.
According to the present invention, the separation treatment can be carried out by a technique known and used by those skilled in the art so that the culture is substantially free of bacterial cells, and includes, but is not limited to: filtration (filtration), centrifugation (centrifugation), and concentration (concentration), and combinations thereof.
As used herein, the term "substantially free" means that the specifically identified component lacks a significant amount. Preferably, the content of the component has no measurable effect on the properties of the culture (measureable effect). More preferably, the culture is completely free of the component.
According to the invention, the culture is further subjected to a drying treatment to obtain a product in the form of a powder. The drying process may be carried out using techniques well known and customary to those skilled in the art, including, but not limited to: freeze-drying (lyophilization) process, low temperature spray-drying (low temperature spray-drying) process, vacuum evaporation (vacuum evaporation) process, and combinations thereof.
According to the present invention, the composition may be added to edible material (edible material) using standard techniques well known to those skilled in the art, for example, it may be added directly to the edible material, or it may be used to prepare an intermediate composition (premix) such as premix, which is then added to the edible material.
In addition, the composition according to the present invention may further comprise a food additive (food additive) selected from the group consisting of: sorbitol (sorbitol), lactitol (lactitol), lactose (lactise), lactic acid (lactic acid), acesulfame potassium (acesulfame potassium), sucralose (sucralose), and combinations thereof.
Accordingly, the present invention also provides a food product comprising a composition as described above.
According to the present invention, the food product categories include, but are not limited to: milk powder (milk powder), fermented milk (fermented milk), yogurt (yogurt), cheese (butter), beverages (beverages) (e.g., tea, coffee), functional beverages (functional beverages), pasta (flow product), baked foods (baker's), desserts (confectionery), candies (confections), fermented foods (fermented foods), animal feeds (animal feeds), health foods (health foods), and dietary supplements (dietary supplements).
The culture of the lactic acid bacterial strain and the composition according to the present invention were confirmed to be effective in increasing the number of stools through in vivo experiments. Accordingly, the culture of the lactic acid bacterium strain and the composition according to the present invention are expected to have the effect of promoting defecation, and thus can be supplied for use in the preparation of a medicament for promoting defecation.
According to the present invention, the pharmaceutical can be manufactured into a dosage form (nasal form) suitable for oral administration (oral administration) by using techniques well known to those skilled in the art, which include, but are not limited to: sterile powders (shelf powder), lozenges (tablet), tablets (troche), buccal tablets (Lozenge), pills (pellet), capsules (capsule), dispersible powders (dispersible granules) or granules (granules), solutions, suspensions (suspension), emulsions (emulsion), syrups (syrup), elixirs (elixir), syrups (syrup) and the like.
According to the present invention, the pharmaceutical may further comprise a pharmaceutically acceptable carrier (pharmaceutically acceptable carrier) which is widely used in pharmaceutical manufacturing technology. For example, the pharmaceutically acceptable carrier may comprise one or more agents selected from the group consisting of: solvents (solvents), buffers (buffers), emulsifiers (emulsifiers), suspending agents (suspending agents), disintegrating agents (disintegrants), disintegrating agents (disintegrating agents), dispersing agents (dispersing agents), binding agents (binding agents), excipients (excipients), stabilizers (stabilizing agents), chelating agents (chelating agents), diluents (diluents), gelling agents (gelling agents), preservatives (preserving agents) [ e.g. potassium hexadienate ], wetting agents (wetting agents), lubricants (lubricants), absorption delaying agents (absorbing delaying agents), liposomes (lipids), and the like. The selection and amounts of such agents are within the skill and routine skill of those in the art.
The present invention also provides a method for promoting defecation, comprising administering to an individual in need thereof a culture or composition of a lactic acid bacterial strain as described above.
As used herein, the terms "administration" and "administration" are used interchangeably.
According to the invention, the dosage and frequency of administration of the culture of the lactic acid bacterial strain and the composition may vary depending on the following factors: the severity of the disease to be ameliorated, the route of administration, and the weight, age, condition and response of the individual to be ameliorated. Selection of dosages and times for administration is well within the skill and routine skill of those in the art.
The invention also provides the application of the culture and the composition of the lactobacillus strain in preparing medicines for treating and/or preventing constipation. Furthermore, the present invention also provides a method for treating an individual having or suspected of having constipation comprising administering to the individual a culture or composition of a lactic acid bacterial strain as described above.
As used herein, the term "treating" or "treatment" of constipation means that the severity of the constipation (severity) or symptoms of the constipation (symptom) is reduced (reduced), or the constipation is partially (parallel) or completely (incident) eliminated (affected).
As used herein, the terms "preventing" or "prevention" of constipation means eliminating (eliminite) or reducing (reduce) the incidence (incidence) of the constipation, and slowing (slow), delaying (delay), controlling (control) or reducing (clear) the likelihood (likelihood) or probability (probability) of the constipation, when an individual has not been diagnosed with the constipation.
According to the present invention, the culture of the lactic acid bacterial strain and the administration form, administration route and pharmaceutically acceptable carrier for use of the composition are as described above.
The invention will be further described with respect to the following examples, but it should be understood that the examples are for illustration only and should not be construed as limiting the practice of the invention.
< example >
General experimental materials:
1. lactobacillus salivarius subsp. sp.salicinus AP-32, Bifidobacterium animalis subsp.lactis CP-9, and Lactobacillus acidophilus (Lactobacillus acidophilus) TYCA06 used in this example have been deposited respectively at the biological resource preservation and Research Center (Bioresource Collection and Research Center, BCRC) of Food Industry Development Institute (Food Industry Research and Development Institute, FIRDI) in taiwan (300 new bamboo Food road No. 331, taiwan), the common microbial Center of the microbial species management society of China (ceramic biological Culture Collection Center, cc), and the Collection Center of typical Culture Collection (ccttype Collection), and are available. For clarity, information on the respective strains of lactic acid bacteria (including accession numbers and accession dates, etc.) is shown in Table 1 below.
TABLE 1 accession number and accession date of the respective strains of lactic acid bacteria
2. The Lactobacillus salivarius subspecies Salicariin L-333 and Lactobacillus acidophilus L-6 used in this example were isolated by the applicant from the intestinal tract of healthy humans, and the Bifidobacterium animalis subspecies Lactobacillus L-53 was isolated by the applicant from the breast milk of healthy humans.
3. The components of the extract used in this example and their sources have been integrated in table 2 below.
TABLE 2 components of the extract and their sources
| Components | Source |
| Black date extract (product name is black date extract) | Hippodamia Biotech Co Ltd |
| Cassia seed extract | Light products Co Ltd |
| Lotus leaf extract | Xinle kang Co., Ltd |
4. The types and sources of dietary supplements used in this example are integrated in Table 3 below.
TABLE 3 type and Source of dietary supplement
Example 1 preparation of the cultured product of lactic acid bacteria of the present invention
First, 6 lactobacillus strains described in items 1 and 2 above were inoculated into MRS medium (purchased from shin-biosciences, Inc.) respectively and cultured at 30-40 ℃ for 12-24 hours, and the resulting culture was used as an inoculum (inoculum). Then, each inoculum source was inoculated into MRS medium separately and cultured at 30-40 ℃ for 12-24 hours. Thereafter, the cells were precipitated by centrifugation, and the supernatant was collected and subjected to heat sterilization treatment. Subsequently, the obtained filtrate containing no cell bodies was subjected to spray-drying treatment (spray-drying treatment), thereby obtaining each of the cultured lactic acid bacteria products.
In a preliminary test, the applicant mixed each lactic acid bacteria culture with maltodextrin (maltodextrin) to prepare capsules containing different cultures and then allowed the subjects to take these capsules 3 times a day for a total of 1 month. During the last week of the dosing period, it was found by recording the number of bowel movements of the subject: the culture products of Lactobacillus salivarius subspecies salicin AP-32(CCTCC M2011127), Bifidobacterium animalis subspecies Lactobacillus lactis CP-9(CCTCC M2014588) and Lactobacillus acidophilus TYCA06(CGMCC NO.15210) have better defecation-promoting effect (data not shown). Therefore, the applicant selected these 3 lactic acid bacteria culture products to perform the following experiments.
Example 2 preparation of a lactic acid bacteria beverage according to the invention
The experimental method comprises the following steps:
first, the extract according to item 3 of the above "experimental material" and the dietary supplement according to item 4 were prepared into a control drink containing no cultured product of lactic acid bacteria according to the following table 4.
TABLE 4 formulation of control drink
Next, 3 lactic acid bacteria beverages were formulated, substantially in reference to the formulation of the control beverage above, except that: these 3 lactic acid bacteria drinks were additionally supplemented with the lactic acid bacteria culture product obtained according to example 1 above, as shown in table 5 below.
TABLE 5 Lactobacillus culture products contained in different Lactobacillus drinks
Example 3 evaluation of the effectiveness of the lactic acid bacteria drink of the present invention in promoting defecation
Experimental subjects:
the subjects participating in the test were employees from toyowa biotechnology, ltd, and after screening with the exclusion criteria (exclusion criteria) shown in table 6 below, the test consisted of 36 subjects aged 25 to 50 years, including 13 males and 23 females.
TABLE 6 exclusion criteria for screening of experimental individuals
| Order of item | Description of the invention |
| 1 | Pregnant woman |
| 2 | Lactating women |
| 3 | Smoker's mouth |
| 4 | Abuse or addiction to alcohol, drugs |
The experimental method comprises the following steps:
first, before all subjects were tested, their number of bowel movements within 24 hours was recorded. Next, all subjects were randomly divided into 4 groups (each group n-9) including 3 experimental groups (i.e., experimental groups 1 to 3) and 1 control group, wherein subjects in experimental groups 1 to 3 were administered 50mL of lactic acid bacteria drinks 1 to 3, respectively, and subjects in the control group were administered 50mL of control drinks. Within 24 hours after administration, their number of stools was recorded. The above experiment was repeated 3 times, each time interval was 1 week, and each subject was assigned to different groups in turn in different experiments, so as to avoid the influence of individual differences of the subjects on the experiment results.
Then, the percentage (%) of the number of the persons who increased and decreased the number of the stools in each group was calculated according to the change of the number of the stools recorded before and after the administration of all the subjects.
The experimental data obtained are expressed as "standard error of the mean (SEM)" as the mean ± the standard error of the mean. All data were analyzed by two-tailed Steed Student's t-test to assess variability between groups. If the statistical analysis result obtained is p < 0.05, it indicates statistical significance (statistical significance).
As a result:
FIG. 1 shows the percentage of people who increased or decreased the number of stools for each group before and after taking the medicine. As can be seen from FIG. 1, the percentage of the population in each experimental group was significantly higher than that in the control group, with the increase being most significant in experimental group 3. The percentage of the population in the control group was significantly higher than that in each of the experimental groups, as far as the number of people who had a decreased number of stools was concerned. The results of this experiment show that: the effect of the combination of any one of the culture products of the subspecies salicylide AP-32(CCTCC M2011127), the subspecies lacticum Lactobacillus animalis CP-9(CCTCC M2014588) and the Lactobacillus acidophilus TYCA06(CGMCC NO.15210) and the three extracts of the dateplum persimmon extract, the cassia seed extract and the lotus leaf extract on the defecation promotion is obviously better than the effect of the combination only containing the three extracts. In particular, a change in the number of stools was observed after one day of administration. Therefore, these lactic acid bacteria culture products and extracts are expected to be used in combination to effectively promote defecation and treat and/or prevent constipation (constipation).
All patents and publications cited in this specification are herein incorporated by reference in their entirety. In conflict, the present specification, including definitions, will control.
While the invention has been described with reference to the specific embodiments described above, it will be apparent that numerous modifications and variations can be made without departing from the scope and spirit of the invention. It is therefore intended that the invention be limited only as indicated by the claims appended hereto.
Biological material preservation information description
The preservation number is: CCTCC NO: m2011127
And (3) classification and naming: lactobacillus salivarius subsp.salicinus (AP-32)
The preservation date is as follows: 2011 4 months and 10 days
The preservation unit: china center for type culture Collection
The address of the depository: chinese Wuhan dynasty
The preservation number is: CCTCC NO: m2014588
And (3) classification and naming: bifidobacterium animalis subsp.lactis CP-9
The preservation date is as follows: 11/24/2014
The preservation unit: china center for type culture Collection
The address of the depository: chinese Wuhan dynasty
The preservation number is: CGMCC No.15210
And (3) classification and naming: lactobacillus acidophilus (Lactobacillus acidophilus) TYCA06
The preservation date is as follows: 15/1/2018
The preservation unit: china general microbiological culture Collection center
The address of the depository: chinese Beijing
Claims (8)
1. A composition for promoting defecation, characterized by: the composition comprises:
black date extract;
a cassia seed extract;
a lotus leaf extract; and
a culture of a lactic acid bacterial strain, wherein said lactic acid bacterial strain is selected from the group consisting of: lactobacillus salivarius subsp.salicinus AP-32(CCTCC M2011127), Bifidobacterium animalis subsp.lactis CP-9(CCTCC M2014588), Lactobacillus acidophilus (Lactobacillus acidophilus) TYCA06(CGMCC NO.15210), and combinations thereof, and the culture is substantially free of bacterial cells.
2. The composition of claim 1, wherein: the composition comprises, based on the total weight of the composition:
1-20% (w/w) of black date extract;
0.1-10% (w/w) of semen Cassiae extract;
0.1-10% (w/w) of lotus leaf extract; and
1-10% (w/w) of a culture of a lactic acid bacterial strain.
3. A food product characterized by: the food product comprising the composition according to any one of claims 1 to 2.
4. Use of a composition according to any one of claims 1 to 2 for the preparation of a medicament for promoting defecation.
5. Use of a composition according to any one of claims 1 to 2 for the preparation of a medicament for the treatment and/or prevention of constipation.
6. Use of a culture supply of a lactic acid bacterial strain for the preparation of a medicament for promoting defecation, characterized in that: the lactic acid bacterial strain is a bacterial strain selected from the group consisting of: lactobacillus salivarius subspecies salicin AP-32(CCTCC M2011127), Bifidobacterium animalis subspecies lactis CP-9(CCTCC M2014588), Lactobacillus acidophilus TYCA06(CGMCC NO.15210), and combinations thereof, and the culture is substantially free of thalli.
7. Use of a culture supply of a lactic acid bacterial strain for the preparation of a medicament for the treatment and/or prevention of constipation, characterized in that: the lactic acid bacterial strain is a bacterial strain selected from the group consisting of: lactobacillus salivarius subspecies salicin AP-32(CCTCC M2011127), Bifidobacterium animalis subspecies lactis CP-9(CCTCC M2014588), Lactobacillus acidophilus TYCA06(CGMCC NO.15210), and combinations thereof, and the culture is substantially free of thalli.
8. Use according to any one of claims 4 to 7, characterized in that: the pharmaceutical is in a dosage form for oral administration.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010774369.3A CN114053342A (en) | 2020-08-04 | 2020-08-04 | Composition for promoting defecation and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010774369.3A CN114053342A (en) | 2020-08-04 | 2020-08-04 | Composition for promoting defecation and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114053342A true CN114053342A (en) | 2022-02-18 |
Family
ID=80232026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010774369.3A Pending CN114053342A (en) | 2020-08-04 | 2020-08-04 | Composition for promoting defecation and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114053342A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103798392A (en) * | 2014-03-07 | 2014-05-21 | 内蒙古伊利实业集团股份有限公司 | Probiotics food composition with function of relieving inflammation of throat and food |
| CN105985918A (en) * | 2014-10-31 | 2016-10-05 | 安徽锦乔生物科技有限公司 | Anti-obesity lactic acid bacteria strain and application thereof in food composition and medical composition |
-
2020
- 2020-08-04 CN CN202010774369.3A patent/CN114053342A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103798392A (en) * | 2014-03-07 | 2014-05-21 | 内蒙古伊利实业集团股份有限公司 | Probiotics food composition with function of relieving inflammation of throat and food |
| CN105985918A (en) * | 2014-10-31 | 2016-10-05 | 安徽锦乔生物科技有限公司 | Anti-obesity lactic acid bacteria strain and application thereof in food composition and medical composition |
Non-Patent Citations (1)
| Title |
|---|
| 孙定人等, 天津科技翻译出版公司 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1759597B1 (en) | Probiotic composition | |
| EP3124031B1 (en) | Sleep quality improver | |
| CN102274245B (en) | Novel lactacidophilus, composition thereof and use thereof in preparation of medicines for relieving diabetes mellitus and complications | |
| CN109123295A (en) | A kind of probiotics solid beverage and preparation method thereof | |
| CN102935092B (en) | Novel lactobacilli and composition thereof, and application thereof in preparing medicines used for ameliorating diabetes and complications thereof | |
| US20180264054A1 (en) | Lactobacillus plantarum tci378 and its uses in losing fat and improving gastrointestinal functions | |
| CN111972670A (en) | Composition for relaxing bowel, solid beverage and application | |
| JP7280069B2 (en) | A composition for preventing or improving functional gastrointestinal disorders, and pharmaceutical compositions and food and drink compositions using the composition for preventing or improving functional gastrointestinal disorders | |
| CN113855712B (en) | Composition capable of promoting defecation and application thereof | |
| US20120301505A1 (en) | Immunostimulating Agent and Method for Production Thereof | |
| CN117487683A (en) | Probiotic composition with effects of resisting claustration, protecting stomach, promoting digestion and removing food retention and application thereof | |
| CN111212575A (en) | Composition for muscle building | |
| JP5953406B2 (en) | Cancer risk reduction agent | |
| CN108795823B (en) | It is a kind of improve women pregnant and lying-in women's intestinal flora probiotics cultural method and application | |
| KR102146706B1 (en) | Composition for improving allergic rhinitis containing fermented red ginseng concentrate having increased content of ginsenoside Rd using fermentation by Bifidobacterium animalis ssp. lactis HY8002 and Bifidobacterium adolescentis HY8502 mixture as effective component | |
| KR100865075B1 (en) | Novel probiotic strain Lactobacillus sp. SM1 showes high cell adherence | |
| CN114686405B (en) | Bifidobacterium bifidum with functions of reducing fat, relieving hyperglycemia and regulating intestinal immunity and application thereof | |
| CN114053342A (en) | Composition for promoting defecation and application thereof | |
| US11969447B2 (en) | Use of spray-dried powder derived from lactic acid bacterial strains and herbal extracts for promoting defecation | |
| US20210401906A1 (en) | Composition for promoting defecation and uses thereof | |
| US20240139261A1 (en) | Composition for improving gut microbiota and method for improving gut microbiota with the composition thereof | |
| TW202335676A (en) | Intestine immunostimulant and IgA generation promoter for ensuring Apilactobacillus lactobacillus having IgA generation promotion effect and immunostimulation function | |
| CN116349815A (en) | Production formula of viable bacteria type probiotic solid beverage capable of regulating intestinal flora | |
| CN115466687A (en) | Composition for reducing body fat content and body weight and application thereof | |
| CN116940247A (en) | Composition for regulating gastric motility function |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20221122 Address after: No. 2, Jingyi Road, Huai'an Economic and Technological Development Zone, Huai'an City, Jiangsu Province Applicant after: JINQIAO BIOTECHNOLOGY CO.,LTD. Address before: 2 / F 4 / F, 17 international road, Xinshi District, Tainan City, Taiwan, China Applicant before: GLAC BIOTECH Co.,Ltd. |
|
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220218 |